Meriofert

Follicle-Stimulating Hormone; Luteinising Hormone, the active ingredient in Meriofert, is a gonadotropin presented as a sterile injectable solution for intramuscular or subcutaneous use. It is employed to stimulate ovarian follicular development and ovulation in women with infertility disorders.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert is a gonadotropin used in reproductive medicine to address disorders of ovarian function. - Infertility due to anovulation: promotes follicular growth and restores ovulation. - Assisted reproductive technology (ART): enhances follicular response for controlled ovarian stimulation in IVF cycles. - Hypogonadotropic hypogonadism: replaces deficient endogenous FSH and LH to initiate normal ovarian activity.

Adverse reactions may occur with any injectable gonadotropin therapy.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the administration site. - Abdominal discomfort: transient bloating or cramping. - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Mild ovarian hyperstimulation syndrome: mild abdominal distension and weight gain. - Pelvic pain: short‑lasting discomfort.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome: rapid weight gain, severe abdominal pain, and fluid accumulation. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Anaphylactic reaction: hives, swelling, or difficulty breathing. - Pulmonary edema: shortness of breath with fluid in lungs. - Severe abdominal pain: may indicate ovarian torsion. - Vision changes: blurred vision or visual disturbances.

Before initiating Meriofert, clinicians should assess patient history and monitor response closely. - Assess baseline ovarian reserve: evaluate antral follicle count and hormone levels. - Monitor estradiol levels: adjust dose to avoid excessive stimulation. - Screen for contraindications: exclude patients with ovarian cysts or uncontrolled thyroid disease. - Counsel on signs of ovarian hyperstimulation: educate patients to report rapid weight gain or severe abdominal pain. - Review concomitant medications: avoid drugs that may exacerbate thrombotic risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert may interact with other agents that influence ovarian response or coagulation.

Major Interactions (Avoid): - GnRH agonists used concurrently: may cause excessive ovarian stimulation. - High‑dose estrogen therapy: can diminish gonadotropin effectiveness. - Anticoagulants (e.g., warfarin): increased risk of bleeding with ovarian hyperstimulation.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may require a washout period before starting therapy. - Thyroid hormone replacement: monitor thyroid function as altered hormone levels affect response. - Antidiabetic agents: hyperstimulation can affect glucose control; monitor blood sugar.